UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20260071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Bingge Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Department of Pathophysiology, School of Basic Medici…. Hauptthemen laut MEDLINE: Aging, Signal Transduction, Motor Activity. Die Arbeit nennt 76 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aging, characterized by progressive physiological decline and systemic dysfunction, represents a major risk factor for age-related diseases such as sarcopenia, which involves fibrosis that disrupts muscle regeneration and function. Effective therapeutic strategies remain limited. Here we report UA-30, a novel compound with a favorable pharmacokinetic and safety profile, that delayed systemic aging in naturally aged mice, as indicated by reduced frailty, slowed epigenetic age, extended lifespan, and improved muscle function. 10-wk UA-30 treatment reduced fibrosis and muscle atrophy in 18.5-mo-old mice. Thermal proteome profiling, surface plasmon resonance, and functional analyses identified Ras-related protein Ral-A (RalA) as a direct molecular target of UA-30. UA-30 suppressed RalA activity, thereby inhibiting the pro-fibrotic JNK–Smad signaling axis and enhancing mitochondrial functions. Overexpression of constitutively active RalA largely abolished the anti-aging and anti-fibrotic effects of UA-30. These findings support UA-30 as a promising therapeutic candidate for aging and sarcopenia, and indicate RalA is a potential target for age-related muscle degeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Tongji M…
- Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
- Department of Neurology, Clinical Neuroscience Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Co-innovation Center of Neuroregeneration, Nantong University , Nantong, China.
ORCID-Profile: Bingge Zhang, Ye He, Ruiming Zhang, Ting Su, Ruijuan Liu, Xiaomei Li, Xiufen Zhang, Bocheng Xiong, Chao Yang, Xinlei Liu, Qian Liu, Qinghua Hou, Yongmei Xie, Gongping Liu, Xifei Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, B., He, Y., Zhang, R., Su, T., Liu, R., Li, X., Zhang, X., Xiong, B., Yang, C., Liu, X., Liu, Q., Hou, Q., Xie, Y., Liu, G., & Yang, X. (2026). UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20260071
Vancouver
Zhang B, He Y, Zhang R, Su T, Liu R, Li X, et al. UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20260071
BibTeX
@article{Zhang2026,
author = {Zhang, Bingge and He, Ye and Zhang, Ruiming and Su, Ting and Liu, Ruijuan and Li, Xiaomei and Zhang, Xiufen and Xiong, Bocheng and Yang, Chao and Liu, Xinlei and Liu, Qian and Hou, Qinghua and Xie, Yongmei and Liu, Gongping and Yang, Xifei},
title = {UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20260071}
}
EUVIMED